Syngene International Q4 FY25 results (Jan–Mar 2025) and concall

Syngene ended FY25 on a solid note with Q4 revenue crossing the ₹1,000 Cr milestone, driven by strong momentum in Biologics and Research Services. However, the company faces a 'transient' FY26 characterized by inventory rebalancing in its animal health business and high operational costs from newly acquired facilities. While underlying demand remains robust with 'early teens' growth expected, reported financials will be dampened by the phase-out of SEZ tax benefits and gestation periods for new capacities.